Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
Featured Showcases
Photonics West Showcase
Optics+Photonics Showcase
Menu
Historical Archive

Germany approves Photofrin

17 Jun 2002

Germany's health authorities have given approval for QLT Photo Therapeutics to market Photofrin, which is used in photodynamic therapy to treatearly-stage lung cancers. Beaufor Ipsen Group, which signed a marketing agreement with QLT last year, will market the drug in Europe. Photofrin will beused specifically for curing patients with early-stage endobronchial large-cell lung cancer who are not undergoing surgery or radiotherapy. (courtesy LaserFocus World)

 
Hamamatsu Photonics Europe GmbHCHROMA TECHNOLOGY CORP.Berkeley Nucleonics CorporationHyperion OpticsHÜBNER PhotonicsIridian Spectral TechnologiesChangchun Jiu Tian  Optoelectric Co.,Ltd.
© 2025 SPIE Europe
Top of Page